img

Coffee company CCL Products' stock saw a massive 15% rise during early trading on Tuesday. The company had released the results for the January-March quarter of the financial year 2025 a day earlier. After good results in the fourth quarter, this stock saw a rise and it was the fastest stock in the Nifty 500 index.

During the January to March quarter, the income growth of CCL Products has increased by 15% as compared to the same quarter of the previous financial year. The company's income in the March quarter was Rs 835.84 crore.

Excellent growth in margin and profit
Apart from this, if we talk about operating profit i.e. EBITDA, it also increased by 38.2% to Rs 163.28 crore on a year-on-year basis. Margin has also seen an expansion of 300 basis points on an annual basis. In the March quarter of the last financial year, the company's EBITDA margin was 16.3%, which has now increased to 19.5% in the March 2025 quarter. The company's net profit also stood at Rs 101.86 crore with a growth of 56%. Earlier, in a special conversation with CNBC-TV18, the management had said that the volume growth in the financial year 2025 could be between 10% and 20%. 

Analyst's bullish view on the stock CCL Products has been included in the coverage list of 11 analysts, out of which none of the analysts have given SELL rating on the stock. 8 out of 11 analysts have advised BUY on the stock. Apart from this, the remaining 3 analysts have advised to hold the stock. All these analysts expect an average rise of 15.5% in the stock. 

Biggest intraday rise in 4 years On Tuesday, this stock was seen trading at a price of Rs 687 per share with a gain of 15.9% intraday at one time. This is the biggest intraday rise in the stock since July 2021. With this rise, the market capitalization of this company has now also crossed Rs 1,000 crore. In the last one month, this stock has seen a rise of 22%. The stock has seen a great rise as compared to the 52-week low of Rs 525 per share. 


Read More: Trump Big Decision: Donald Trump's big decision on the pharma sector, will take another decision in 15 days

--Advertisement--